AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Pharmaceutical Investing
Verastem Oncology and Yakult Honsha Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan Pharmaceutical Investing
Chugai’s HEMLIBRA Receives Priority Review Status from U.S. FDA for Hemophilia A Without Inhibitors Pharmaceutical Investing
FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People with Hemophilia A without Factor VIII Inhibitors Genetics Investing
Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations Pharmaceutical Investing
LYNPARZA (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Pharmaceutical Investing
TESARO Announces Collaboration to Evaluate ZEJULA in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer Pharmaceutical Investing
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress Pharmaceutical Investing
Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis Biotech Investing
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder Pharmaceutical Investing
